Head and neck cancer is estimated to result in 71,000 new cancer diagnoses and 16,000 deaths in 2024. Of these cases, approximately 14% will be metastatic. Recent changes in treatment paradigms have established immunotherapy as a cornerstone of treatment in the metastatic and recurrent setting. While immunotherapy has undoubtedly improved outcomes and can lead to long term durable responses in select patients, overall response rates remain suboptimal, with approximately 13%-20% of patients responding to immunotherapy in most studies. This review aims to provide an overview of the current treatment landscape of immunotherapies in head and neck malignancies. Additionally, we aim to discuss the future of immunotherapy, as well as novel targets and therapeutic platforms that may continue to change the treatment paradigm in this disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.semradonc.2025.02.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Survivorship Paradigms in Head/Neck Cancer.
Semin Radiat Oncol
April 2025
Department of Radiation Oncology, Northwestern University, Chicago, IL; Department of Medical Social Sciences, Northwestern University, Chicago, IL. Electronic address:
Long-term care for head and neck cancer (HNC) survivors is complex. Despite an improvement in survival and the evolution of treatment paradigms (de-escalation, targeted therapy), notably in the context of human papillomavirus (HPV)-related oropharyngeal cancers, HNC survivors still experience a wide range of side effects and needs, which impact their functionality, quality of life, survival and require concerted, coordinated survivorship care. In this review, we perform an overview of existing HNC survivorship recommendations within the context of novel evidence, our current understanding of survivorship care, and incorporate them into the Nekhluydov Survivorship Care Framework.
View Article and Find Full Text PDFRadiation-Therapy Related Salivary Dysfunction.
Semin Radiat Oncol
April 2025
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.; University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI.. Electronic address:
Radiation-induced xerostomia (RIX) is a common and debilitating side effect of head and neck cancer radiotherapy, significantly impacting patients' quality of life. This review comprehensively summarizes the current understanding of RIX, encompassing its clinical quantification, underlying pathophysiology, and established and emerging treatment modalities. We explore various objective and subjective measures used to quantify salivary flow and assess the severity of xerostomia in clinical settings.
View Article and Find Full Text PDFOral Mucositis in Head and Neck Cancer Patients.
Semin Radiat Oncol
April 2025
Department of Dental Oncology, North East Cancer Centre, Health Sciences North, Northern Ontario School of Medicine University, Sudbury, ON.
Oral mucositis (OM) is a common side effect of radiation therapy for head and neck cancer (HNC). Despite the medical advances in cancer therapy, OM is still virtually inevitable in patients being irradiated for neoplasms of the head and neck. The initial signs of oral mucositis typically manifest after cumulative doses between 15 and 20 Gy, with ulceration formation by 30 Gy and reaching peak severity in the week after radiation treatment completion (generally 60-72 Gy in management of HNC), then resolving over the 3-4 weeks following treatment completion.
View Article and Find Full Text PDFMetastatic Head and Neck Cancer: Immunotherapy and Beyond.
Semin Radiat Oncol
April 2025
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.. Electronic address:
Head and neck cancer is estimated to result in 71,000 new cancer diagnoses and 16,000 deaths in 2024. Of these cases, approximately 14% will be metastatic. Recent changes in treatment paradigms have established immunotherapy as a cornerstone of treatment in the metastatic and recurrent setting.
View Article and Find Full Text PDFReirradiation for Locally Recurrent Head and Neck Cancer: State-of-the-Art and Future Directions.
Semin Radiat Oncol
April 2025
Department of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX.
Reirradiation of the head and neck presents one of the most complex and challenging scenarios faced by (for) clinicians due to the narrow therapeutic window. Its use is increasing in clinical practice, often guided by empirical and pragmatic approaches due to the limited availability of high-level evidence from randomized clinical trials. Successful reirradiation requires a precise balance between tumor control probability (TCP) and normal tissue complication probability (NTCP).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!